Review anchor
Cyclin-G-associated kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Cyclin-G-associated kinase
CHEMBL4355
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cyclin-G-associated kinase as ChEMBL target CHEMBL4355, mapped to UniProt O14976. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4355
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O14976
Cyclin-G-associated kinase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Cyclin-G-associated kinase matters
Cyclin-G-associated kinase is reviewed as Cyclin-G-associated kinase (UniProt O14976); the current evidence base includes 31 approved drugs, 866 compounds, and 255 assays, with lead potency reaching pChEMBL 10.2.
Protein context
Cyclin-G-associated kinase
Cyclin-G-associated kinase Sequence length is 1311 aa.
Review this target as Cyclin-G-associated kinase, mapped to UniProt O14976. Sequence length is 1311 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O14976
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 31 approved drugs, 866 compounds, and 255 assays for this target. The dominant activity type is KD. CHEMBL4531690 is the current potency anchor at pChEMBL 10.2.
Use CHEMBL4531690 as the tractability anchor when discussing potency (pChEMBL 10.2).
Activity source · ChEMBL 36 via Core Engine
31 approved
pChEMBL 10.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Cyclin-G-associated kinase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O14976, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
866
Total Compounds
255
Total Assays
31
Approved Drugs
IC50: 145.0, KI: 28.0, EC50: 11.0, KD: 599.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4531690
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL3545396
|
9.5 | Kd | Clinical |
|
|
No preferred name
CHEMBL81073
|
9.4 | Kd | — |
|
|
No preferred name
CHEMBL5415503
|
9.0 | Kd | — |
|
|
No preferred name
CHEMBL1287853
|
9.0 | IC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MOMELOTINIB
CHEMBL1078178
|
2023 |
|
|
PACRITINIB
CHEMBL2035187
|
2022 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
GILTERITINIB
CHEMBL3301622
|
2018 |
|
|
DACOMITINIB ANHYDROUS
CHEMBL2110732
|
2018 |
|
|
RIBOCICLIB
CHEMBL3545110
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
BARICITINIB
CHEMBL2105759
|
2017 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
ALECTINIB
CHEMBL1738797
|
2015 |
|
|
AFATINIB
CHEMBL1173655
|
2013 |
|
|
AFATINIB DIMALEATE
CHEMBL2105712
|
2013 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
GEFITINIB
CHEMBL939
|
2003 |
|
|
IMATINIB
CHEMBL941
|
2001 |
Source Header